Candesartan
- Generic Name
- Candesartan
- Brand Names
- Atacand, Atacand Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H20N6O3
- CAS Number
- 139481-59-7
- Unique Ingredient Identifier
- S8Q36MD2XX
- Background
Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.
- Indication
May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
- Associated Conditions
- Hypertension, NYHA Functional Class II-IV Heart Failure
Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Hospital Israelita Albert Einstein
- Target Recruit Count
- 698
- Registration Number
- NCT05920005
- Locations
- 🇧🇷
Vitoria Clinical Research Institute LTDA, Vitória, Espírito Santo, Brazil
🇧🇷Instituto Atena de Pesquisa Clinica LTDA, Natal, Rio Grande Do Norte, Brazil
🇧🇷Centro de Pesquisas Clinicas Dr. Marco Mota (Centro Universitario Cesmac/ Hospital do Coração de Alagoas), Maceió, Alagoas, Brazil
Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury
- Conditions
- Traumatic Brain Injury
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 672
- Registration Number
- NCT05826912
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Post-traumatic Headache Multidisciplinary Study
- Conditions
- Post-Traumatic HeadachePost-Concussion Syndrome
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 58
- Registration Number
- NCT05328635
- Locations
- 🇩🇰
Danish Headache Center, Glostrup, Denmark
Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Cristina Avendaño Solá
- Target Recruit Count
- 320
- Registration Number
- NCT05321875
- Locations
- 🇪🇸
Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain
Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19
- Conditions
- COVID-19SARS-CoV2 Infection
- Interventions
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- University of Sydney
- Target Recruit Count
- 49
- Registration Number
- NCT05122182
- Locations
- 🇮🇳
DM Wayanad Institute of Medical Sciences, Meppadi, India
🇮🇳Sterling Hospital, Nigdi, India
🇮🇳Jivanrekha Multi-Speciality Hospital, Pune, India
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
- Conditions
- SARS-CoV InfectionCovid19
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 341
- Registration Number
- NCT04606563
- Locations
- 🇨🇦
Royal Jubilee Hospital, Nanaimo, British Columbia, Canada
🇨🇦St Paul's Hospital, Vancouver, British Columbia, Canada
🇨🇦The Ottawa Hospital, Ottawa, Ontario, Canada
Candesartan for Migraine Prevention:
- Conditions
- Migraine
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- St. Olavs Hospital
- Target Recruit Count
- 450
- Registration Number
- NCT04574713
- Locations
- 🇪🇪
Tartu University Clinics, Tartu, Estonia
🇳🇴Nordland Hospital, Bodø, Norway
🇳🇴Akershus University Hospital AHUS, Lørenskog, Norway
Candesartan as an Adjunctive Treatment for Bipolar Depression
- Conditions
- Bipolar Disorder Depression
- Interventions
- Drug: Placebo
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer
- Conditions
- CardiotoxicityBreast CancerAdjuvantTrastuzumabPrevention
- Interventions
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 136
- Registration Number
- NCT04429633
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)
- Conditions
- COVID-19
- Interventions
- Other: Best standard of careDrug: non-RAS blocking antihypertensivesDrug: Thromboprophylaxis
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 500
- Registration Number
- NCT04351724
- Locations
- 🇦🇹
Medical University of Innsbruck, Innsbruck, Tirol, Austria
🇦🇹Wilhelminenspital, Vienna, Austria
🇦🇹SMZ Ost Donauspital, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.